NCT04310241 Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy
| NCT ID | NCT04310241 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Cleveland Clinic |
| Condition | Amblyopia |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2020-02-21 |
| Primary Completion | 2027-03-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2020-02-21 with a primary completion date of 2027-03-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Amblyopia and strabismus are characterized by a reduction in visual acuity, contrast sensitivity, grating acuity, vernier acuity, reading difficulties and binocular visual function deficits. Treated patients have residual visual function deficits. The purpose of the current study is to quantify various visual functions in amblyopic and strabismic participants at baseline, during and at the completion of treatment.
Eligibility Criteria
Inclusion Criteria: * History of amblyopia or presence of amblyogenic risk factors. Exclusion Criteria: * History of neurologic disorders
Contact & Investigator
Fatema Ghasia, MD
PRINCIPAL INVESTIGATOR
The Cleveland Clinic
Frequently Asked Questions
Who can join the NCT04310241 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 90 Years, studying Amblyopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04310241 currently recruiting?
Yes, NCT04310241 is actively recruiting participants. Contact the research team at baynesk@ccf.org for enrollment information.
Where is the NCT04310241 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT04310241 clinical trial?
NCT04310241 is sponsored by The Cleveland Clinic. The principal investigator is Fatema Ghasia, MD at The Cleveland Clinic. The trial plans to enroll 150 participants.